Department of Cell Biology and Physiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
Division of Genetics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.
Dis Model Mech. 2023 Nov 1;16(11). doi: 10.1242/dmm.050208. Epub 2023 Nov 17.
Wilms tumors present as an amalgam of varying proportions of tissues located within the developing kidney, one being the nephrogenic blastema comprising multipotent nephron progenitor cells (NPCs). The recurring missense mutation Q177R in NPC transcription factors SIX1 and SIX2 is most correlated with tumors of blastemal histology and is significantly associated with relapse. Yet, the transcriptional regulatory consequences of SIX1/2-Q177R that might promote tumor progression and recurrence have not been investigated extensively. Utilizing multiple Wilms tumor transcriptomic datasets, we identified upregulation of the gene encoding non-canonical WNT ligand WNT5A in addition to other WNT pathway effectors in SIX1/2-Q177R mutant tumors. SIX1 ChIP-seq datasets from Wilms tumors revealed shared binding sites for SIX1/SIX1-Q177R within a promoter of WNT5A and at putative distal cis-regulatory elements (CREs). We demonstrate colocalization of SIX1 and WNT5A in Wilms tumor tissue and utilize in vitro assays that support SIX1 and SIX1-Q177R activation of expression from the WNT5A CREs, as well as enhanced binding affinity within the WNT5A promoter that may promote the differential expression of WNT5A and other WNT pathway effectors associated with SIX1-Q177R tumors.
维尔姆斯瘤表现为在发育中的肾脏内的各种组织的混合物,其中一种是由多能肾祖细胞 (NPC) 组成的肾胚基。NPC 转录因子 SIX1 和 SIX2 中的重复错义突变 Q177R 与胚细胞瘤组织学最相关,并且与复发显著相关。然而,SIX1/2-Q177R 的转录调控后果可能促进肿瘤的进展和复发,尚未得到广泛研究。利用多个威尔姆斯瘤转录组数据集,我们发现除了 SIX1/2-Q177R 突变肿瘤中的其他 WNT 途径效应物外,编码非经典 WNT 配体 WNT5A 的基因上调。来自威尔姆斯瘤的 SIX1 ChIP-seq 数据集显示,在 WNT5A 的启动子内和推定的远端顺式调控元件 (CRE) 内,SIX1/SIX1-Q177R 具有共享的结合位点。我们证明了 SIX1 和 WNT5A 在威尔姆斯瘤组织中的共定位,并利用体外实验证明了 SIX1 和 SIX1-Q177R 激活了 WNT5A CRE 的表达,以及在 WNT5A 启动子内增强了结合亲和力,这可能促进了 WNT5A 和其他与 SIX1-Q177R 肿瘤相关的 WNT 途径效应物的差异表达。